SUDA GOKI

スダゴウキ | SUDA GOKI

Affiliation and department：
Homepage URL (1)： http://kaken.nii.ac.jp/d/r/20447460.ja.html

Research field (1)： Gastroenterology

Research theme for competitive and other funds (18)：

2022 - 2025 肝線維化治療標的同定とそれに基づく新規抗肝線維化治療法開発
2022 - 2025 PARP inhibitor resistance in cancer stem cells in hepatocelular carcinoma
2022 - 2025 食道扁平上皮癌がん幹細胞における免疫逃避機構の解明
2022 - 2025 Comprehensive search for host factors related to liver fibrosis mechanisms and development of novel therapeutic strategies
2021 - 2024 肝癌幹細胞の維持・免疫寛容機構の解明と治療最適化の検討

Show all

Papers (221)：

Mara Persano, Andrea Casadei-Gardini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Federico Rossari, Changhoon Yoo, Jaekyung Cheon, Fabian Finkelmeier, et al. Lenvatinib versus sorafenib second-line therapy in patients with hepatocellular carcinoma progressed to atezolizumab plus bevacizumab: a retrospective real-world study. Oncology. 2024. 1-27
Federico Rossari, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Changhoon Yoo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, José Presa, et al. Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study. Liver cancer. 2024. 13. 5. 522-536
Naohiro Yasuura, Goki Suda, Masatsugu Ohara, Akimitsu Meno, Takuya Sho, Risako Kohya, Takashi Sasaki, Tomoka Yoda, Sonoe Yoshida, Qingjie Fu, et al. Positivity of high-sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non-HBV-related HCC. Alimentary pharmacology & therapeutics. 2024
Shusuke Kumazaki, Hayato Hikita, Yuki Tahata, Ji Hyun Sung, Kenji Fukumoto, Yuta Myojin, Sadatsugu Sakane, Kazuhiro Murai, Yoichi Sasaki, Kumiko Shirai, et al. Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis. Alimentary pharmacology & therapeutics. 2024. 60. 3. 327-339
Sadatsugu Sakane, Hayato Hikita, Kumiko Shirai, Tatsuya Sakamoto, Ryohei Narumi, Jun Adachi, Naruyasu Kakita, Yukinori Yamada, Hidenori Toyoda, Hirokazu Takahashi, et al. Proteomic analysis of serum extracellular vesicles reveals Fibulin-3 as a new marker predicting liver-related events in MASLD. Hepatology communications. 2024. 8. 6

ｍore...

MISC (244)：

Shusuke Kumazaki, Hayato Hikita, Yuki Tahata, Kenji Fukumoto, Kazuhiro Murai, Takahiro Kodama, Naruyasu Kakita, Hirokazu Takahashi, Hidenori Toyoda, Goki Suda, et al. GDF15 IS A NOVEL PREDICTIVE MARKER FOR DEVELOPMENT OF NAFLDASSOCIATED LIVER CANCER. HEPATOLOGY. 2023. 78. S799-S800
中村昭伸, 大江悠希, 久住麻唯子, 宮愛香, 野本博司, 亀田啓, 曹圭龍, 小川浩司, 荘拓也, 須田剛生, et al. 減量・代謝改善手術後の膵β細胞機能改善に肝の脂肪化が関連する. 糖尿病. 2022. 65. Suppl.1. S-153
大原正嗣, 須田剛生, 重沢拓, 鈴木和治, 中村晃久, 川岸直樹, 中井正人, 荘拓也, 森川賢一, 小川浩司, et al. 肝疾患患者における筋肉量の経時変化の評価はBIA法に比べCT画像を用いた方法が有用である. 肝臓. 2021. 62. Supplement 1
須田剛生, 大原正嗣, 坂本直哉. 日本人におけるpsoas muscle mass index最適cut-off値の検討と肝疾患患者における検討. 日本消化器病学会雑誌(Web). 2021. 118
小川浩司, 中井正人, 荘拓也, 須田剛生, 森川賢一, 坂本直哉. Intrahepatic arterio-venous shunt. 日本臨床. 2021

ｍore...

Lectures and oral presentations (242)：

減量・代謝改善手術後の膵β細胞機能改善に肝の脂肪化が関連する
(糖尿病 2022)
日本人におけるpsoas muscle mass index最適cut-off値の検討と肝疾患患者における検討
(日本消化器病学会雑誌(Web) 2021)
Intrahepatic arterio-venous shunt
(日本臨床 2021)
肝疾患患者における筋肉量の経時変化の評価はBIA法に比べCT画像を用いた方法が有用である
(肝臓 2021)
Comparative Glycomic Analysis by Aminolysis-SALSA method combined with Sialyl Linkage-specific Isotope Labeling.
(日本糖質学会年会要旨集 2020)

ｍore...

Professional career (1)：

医学博士 (東京医科歯科大学)

Work history (1)：

2013 - Hokkaido University

Awards (15)：

2024/10 - 日本肝臓病学会日本肝臓病学会冠アワード
2024/02 - 国立大学法人北海道大学国立大学法人北海道大学教育研究総長表彰(研究受賞)
2023/12 - ロシュ・ダイアグノスティックス株式会社 Roche Infectious Disease Award
2022 - The 31st Conference of the Asian Pacific Association for Study of the liver (APASL) Travel Award.
2021 - APDWF-JGHF Emerging Leader Award

Show all

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page